Articles related to POLYENDOCRINE METABOLIC OVARIAN SYNDROME (PMOS)

A consumer overview describes metformin’s potential roles in weight management, ovarian syndrome symptoms, and cardiovascular outcomes, but the reported findings involve different populations and do not establish equivalent benefits across these uses.

PCOS was associated with significantly elevated risk for breast, uterine, ovarian/fallopian tube, and cervical cancers in a matched cohort of more than 2.5 million women.

A JCEM clinical guidance article outlines a two-criterion diagnostic standard for adolescent PCOS, requiring both persistent hyperandrogenism and menstrual irregularity, and frames adolescence as the critical window for metabolic and psychosocial risk stratification.

A 14-year international consensus effort involving 56 professional and patient organizations has renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome, a shift designed to better reflect the condition’s systemic hormonal and metabolic pathophysiology.

An international consensus involving more than 14,000 patients and health professionals renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to reflect its endocrine and metabolic features.

A clinical review outlines how OBGYNs can integrate GLP-1 receptor agonist therapy into obesity care for women of reproductive age, with attention to fertility, contraception, and adherence.